Agilent (A) 10-Q 1 Jun 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Apr. 30, 2021	May 21, 2021
Document and Entity Information [Abstract]
Entity Registrant Name	AGILENT TECHNOLOGIES, INC.
Document Type	10-Q
Document Fiscal Period Focus	Q2
Document Period End Date	Apr. 30, 2021
Current Fiscal Year End Date	--10-31
Document Fiscal Year Focus	2021
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Entity Central Index Key	0001090872
Entity File Number	001-15405
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0518772
Entity Address, Address Line One	5301 Stevens Creek Blvd.,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95051
City Area Code	(800)
Local Phone Number	227-9770
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	A
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		303,443,225

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Net revenue:
Net revenue	$ 1,525	$ 1,238	$ 3,073	$ 2,595
Costs and expenses:
Cost of revenue	708	581	1,418	1,215
Research and development	109	197	212	301
Selling, general and administrative	420	358	827	762
Total costs and expenses	1,237	1,136	2,457	2,278
Income from operations	288	102	616	317
Interest income	1	3	1	6
Interest expense	(20)	(20)	(39)	(40)
Other income (expense), net	4	36	7	57
Income before taxes	273	121	585	340
Provision for income taxes	57	20	81	42
Net income	$ 216	$ 101	$ 504	$ 298
Net income per share
Basic	$ 0.71	$ 0.33	$ 1.65	$ 0.96
Diluted	$ 0.70	$ 0.32	$ 1.64	$ 0.95
Weighted average shares used in computing net income per share:
Basic	304	309	305	310
Diluted	307	312	308	313
Product
Net revenue:
Net revenue	$ 1,150	$ 923	$ 2,322	$ 1,946
Costs and expenses:
Cost of revenue	504	417	1,013	871
Service, Other
Net revenue:
Net revenue	375	315	751	649
Costs and expenses:
Cost of revenue	$ 204	$ 164	$ 405	$ 344

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Net income	$ 216	$ 101	$ 504	$ 298
Other comprehensive income (loss):
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $0, $0 $(2) and $0	0	2	(4)	3
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $2, $0, $4 and $0	4	(1)	10	(1)
Foreign currency translation, net of tax expense (benefit) of $0, $0, $0 and $0	2	(29)	44	(40)
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense of $4, $2, $8 and $5	12	12	21	18
Change in net prior service benefit, net of tax expense (benefit) of $0, $(1), $0 and $0	(1)	(1)	(1)	(4)
Other comprehensive income (loss)	17	(17)	70	(24)
Total comprehensive income	$ 233	$ 84	$ 574	$ 274

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Other comprehensive income (loss), tax, parenthetical disclosures
Unrealized gain (loss) on derivative instruments, tax	$ 0	$ 0	$ (2)	$ 0
Amounts reclassified into earnings related to derivative instruments, tax	2	0	4	0
Foreign currency translation, tax	0	0	0	0
Net defined benefit pension cost and post retirement plan costs, tax
Change in actuarial net loss, tax	4	2	8	5
Change in net prior service benefit, tax	$ 0	$ (1)	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Current assets:
Cash and cash equivalents	$ 1,380	$ 1,441
Accounts receivable, net	1,075	1,038
Inventory	791	720
Other current assets	268	216
Total current assets	3,514	3,415
Property, plant and equipment, net	884	845
Goodwill	4,054	3,602
Other intangible assets, net	1,005	831
Long-term investments	188	158
Other assets	753	776
Total assets	10,398	9,627
Current liabilities:
Accounts payable	423	354
Employee compensation and benefits	386	367
Deferred revenue	429	386
Short-term debt	205	75
Other accrued liabilities	315	285
Total current liabilities	1,758	1,467
Long-term debt	2,727	2,284
Retirement and post-retirement benefits	377	389
Other long-term liabilities	726	614
Total liabilities	5,588	4,754
Commitments and Contingencies (Note 8, 9 and 12)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 303 million shares at April 30, 2021 and 306 million shares at October 31, 2020, issued and outstanding	3	3
Additional paid-in-capital	5,271	5,311
Retained earnings (accumulated deficit)	(12)	81
Accumulated other comprehensive loss	(452)	(522)
Total stockholder's equity	4,810	4,873
Total liabilities and equity	$ 10,398	$ 9,627

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - $ / shares shares in Thousands	Apr. 30, 2021	Oct. 31, 2020
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	125,000	125,000
Preferred Stock, Shares Issued	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000	2,000,000
Common Stock, Shares, Issued	303,000	306,000
Common Stock, Shares, Outstanding	303,000	306,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020
Cash flows from operating activities
Net income	$ 504	$ 298
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	153	155
Share-based compensation	66	44
Deferred taxes	31	(3)
Excess and obsolete inventory related charges	14	9
Loss on extinguishment of debt	17	0
Unrealized gain on equity securities	(11)	(27)
Asset Impairment Charges	2	99
Other non-cash expense, net	2	3
Changes in assets and liabilities:
Accounts receivable	(17)	25
Inventory	(80)	(85)
Accounts payable	51	(10)
Employee compensation and benefits	(3)	(50)
Other assets and liabilities	(19)	(204)
Net cash provided by (used in) operating activities	710	254
Cash flows from Investing activities:
Investments in property, plant and equipment	(72)	(67)
Payment to acquire fair value investments	(8)	(18)
Payment in exchange for convertible note	(2)	(3)
Payments to Acquire Businesses, Net of Cash Acquired	(547)	0
Net cash used in investing activities	(629)	(88)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	26	32
Payment of taxes related to net share settlement of equity awards	(73)	(33)
Payment of dividends	(118)	(111)
Issuance of senior notes	848	0
Payments of Debt Issuance Costs	(7)	0
Proceeds from revolving credit facility	0	798
Repayment of revolving credit facility	0	(713)
Repayment of senior notes	(417)	0
Proceeds from Commercial Paper	1,232	0
Repayments of commercial paper	(1,102)	0
Repayment of finance lease	0	(4)
Treasury stock repurchases	(539)	(186)
Net cash used in financing activities	(150)	(217)
Effect of exchange rate movements	9	(8)
Net decrease in cash, cash equivalents and restricted cash	(60)	(59)
Cash, cash equivalents and restricted cash at beginning of period	1,447	1,388
Cash, cash equivalents and restricted cash at end of period	1,387	1,329
Supplemental cash flow information:
Income tax paid, net	116	286
Interest payments	$ 36	$ 39

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Loss	Total Stockholder's Equity
Beginning Balance (in Shares) at Oct. 31, 2019		309,071
Beginning Balance at Oct. 31, 2019		$ 3	$ 5,277	$ (18)	$ (514)	$ 4,748
Components of comprehensive income, net of tax
Net income	$ 298			298		298
Other comprehensive income (loss)	(24)				(24)	(24)
Total comprehensive income, net of tax						274
Aggregate Dividends declared (Cash)				111		111
Share-based awards issued, net of tax (in shares)		1,761
Share-based awards issued			(1)			(1)
Stock Repurchased and Retired During Period, Shares		(2,389)
Stock Repurchased and Retired During Period, Value			(32)	(154)		(186)
Share-based compensation			44			44
Ending Balance (in Shares) at Apr. 30, 2020		308,443
Ending Balance at Apr. 30, 2020		$ 3	5,288	15	(538)	4,768
Beginning Balance (in Shares) at Jan. 31, 2020		310,048
Beginning Balance at Jan. 31, 2020		$ 3	5,293	73	(521)	4,848
Components of comprehensive income, net of tax
Net income	101			101		101
Other comprehensive income (loss)	(17)				(17)	(17)
Total comprehensive income, net of tax						84
Aggregate Dividends declared (Cash)				55		55
Share-based awards issued, net of tax (in shares)		58
Share-based awards issued			0			0
Stock Repurchased and Retired During Period, Shares		(1,663)
Stock Repurchased and Retired During Period, Value			(22)	(104)		(126)
Share-based compensation			17			17
Ending Balance (in Shares) at Apr. 30, 2020		308,443
Ending Balance at Apr. 30, 2020		$ 3	5,288	15	(538)	4,768
Beginning Balance (in Shares) at Oct. 31, 2020		306,198
Beginning Balance at Oct. 31, 2020		$ 3	5,311	81	(522)	4,873
Components of comprehensive income, net of tax
Net income	504			504		504
Other comprehensive income (loss)	70				70	70
Total comprehensive income, net of tax						574
Aggregate Dividends declared (Cash)				118		118
Share-based awards issued, net of tax (in shares)		1,643
Share-based awards issued			(46)			(46)
Stock Repurchased and Retired During Period, Shares		(4,438)
Stock Repurchased and Retired During Period, Value			(60)	(479)		(539)
Share-based compensation			66			66
Ending Balance (in Shares) at Apr. 30, 2021		303,403
Ending Balance at Apr. 30, 2021		$ 3	5,271	(12)	(452)	4,810
Beginning Balance (in Shares) at Jan. 31, 2021		304,905
Beginning Balance at Jan. 31, 2021		$ 3	5,266	4	(469)	4,804
Components of comprehensive income, net of tax
Net income	216			216		216
Other comprehensive income (loss)	$ 17				17	17
Total comprehensive income, net of tax						233
Aggregate Dividends declared (Cash)				59		59
Share-based awards issued, net of tax (in shares)		51
Share-based awards issued			1			1
Stock Repurchased and Retired During Period, Shares		(1,553)
Stock Repurchased and Retired During Period, Value			(22)	(173)		(195)
Share-based compensation			26			26
Ending Balance (in Shares) at Apr. 30, 2021		303,403
Ending Balance at Apr. 30, 2021		$ 3	$ 5,271	$ (12)	$ (452)	$ 4,810

CONDENSED CONSOLIDATE STATEMENT

CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Statement of Stockholders' Equity [Abstract]
Dividends Declared per share	$ 0.194	$ 0.18	$ 0.388	$ 0.36
Tax related to shares issued	$ 1	$ 0	$ 73	$ 33

OVERVIEW, BASIS OF PRESENTATION

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)	6 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2021 and 2020 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2020 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2020. In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2021 and October 31, 2020, condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2021 and 2020, condensed consolidated statement of operations for the three and six months ended April 30, 2021 and 2020, condensed consolidated statement of cash flows for the six months ended April 30, 2021 and 2020 and condensed consolidated statement of equity for the three and six months ended April 30, 2021 and 2020. Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes. Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: April 30, October 31 2021 2020 (in millions) Cash and cash equivalents $ 1,380 $ 1,441 Restricted cash included in other assets 7 6 Total cash, cash equivalents and restricted cash $ 1,387 $ 1,447 Leases. As of April 30, 2021 and October 31, 2020, operating lease right-of-use assets where we are the lessee were $186 million and $175 million, respectively, and were included within other assets in the accompanying condensed consolidated balance sheet. The associated operating lease liabilities were $191 million and $178 million as of April 30, 2021 and October 31, 2020, respectively, and were included in other accrued liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheet. Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of April 30, 2021 and October 31, 2020, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of April 30, 2021 and October 31, 2020, the total carrying value of investments and loans in privately held companies considered as VIEs was $53 million and $67 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the condensed consolidated balance sheet. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $79 million and $162 million as of April 30, 2021 and October 31, 2020, respectively. The fair value is greater than carrying value primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs (for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies) are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.

NEW ACCOUNTING PRONOUNCEMENTS (

NEW ACCOUNTING PRONOUNCEMENTS (Notes)	6 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NEW ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Pronouncements In June 2016, the FASB issued new guidance to require a financial asset measured at amortized cost basis, such as accounts receivable, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. During 2018 and 2019, the FASB issued additional guidance and clarification. On November 1, 2020, we adopted this guidance which did not have a material impact on our condensed consolidated financial statements. In January 2017, the FASB issued new guidance that simplifies the measurement of goodwill impairment by eliminating the Step 2 requirement that an entity compute the implied fair value of goodwill based on the fair values of its assets and liabilities to measure impairment. Instead, goodwill impairment will be measured as the difference between the fair value of the reporting unit and the carrying value of the reporting unit. The standard also clarifies the treatment of the income tax effect of tax deductible goodwill when measuring goodwill impairment loss. On November 1, 2020, we adopted this guidance which did not have a material impact on our condensed consolidated financial statements. In August 2018, the Financial Accounting Standards Board ("FASB") issued updates to improve the disclosure requirements for fair value measurements in Topic 820, Fair Value Measurement which eliminates certain disclosure requirements and modifies others. On November 1, 2020, we adopted these amendments which did not have a material impact on our consolidated financial statements and disclosures. See Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments disclosures. In December 2019, the FASB issued new guidance to simplify the accounting for income taxes. This guidance eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance also improves consistent application by clarifying and amending existing guidance related to aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step up in the tax basis of goodwill. On November 1, 2020, we early adopted this guidance which did not have a material impact on our condensed consolidated financial statements and disclosures. In March 2020, the FASB issued an update for facilitation of the effects of reference rate reform on financial reporting. This update provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in the guidance provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply to contracts, hedging relationships, and other transactions that reference London Inter-bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. When elected, the optional expedients for contract modifications are applied consistently for all eligible contracts or eligible transactions within the relevant Topic or Industry Subtopic in the FASB's Accounting Standards Codification. The guidance was effective upon issuance and may generally be applied through December 31, 2022 to any new or amended contracts, hedging relationships, and other transactions that reference LIBOR. In January 2021, the FASB issued an update that provides supplemental guidance and clarification of the reference rate reform. The update provides additional optional guidance on the transition from LIBOR to include derivative instruments that use an interest rate for margining, discounting or contract price alignment. The standard will ease, if warranted, the requirements for accounting for the future effects of the rate reform. An entity may elect to apply the amendments prospectively through December 31, 2022. We continue to monitor the impact that the discontinuance of LIBOR or another reference rate will have on our contracts, hedging relationships and other transactions. Accounting Pronouncements Not Yet Adopted There were no additions to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2020. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our condensed consolidated financial statements upon adoption.

REVENUE (Notes)

REVENUE (Notes)	6 Months Ended
	Apr. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer	REVENUE The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Three Months Ended April 30, 2021 2020 Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Revenue by Region Americas $ 231 $ 187 $ 163 $ 581 $ 170 $ 161 $ 126 $ 457 Europe 155 154 106 415 111 131 92 334 Asia Pacific 288 195 46 529 245 157 45 447 Total $ 674 $ 536 $ 315 $ 1,525 $ 526 $ 449 $ 263 $ 1,238 Six Months Ended April 30, 2021 2020 Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Revenue by Region Americas $ 455 $ 366 $ 315 $ 1,136 $ 379 $ 328 $ 244 $ 951 Europe 345 301 206 852 278 264 184 726 Asia Pacific 596 401 88 1,085 507 327 84 918 Total $ 1,396 $ 1,068 $ 609 $ 3,073 $ 1,164 $ 919 $ 512 $ 2,595 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 531 $ 400 $ 1,052 $ 823 Chemical and Energy 314 267 642 579 Diagnostics and Clinical 233 200 449 394 Food 144 114 306 244 Academia and Government 143 115 285 256 Environmental and Forensics 160 142 339 299 Total $ 1,525 $ 1,238 $ 3,073 $ 2,595 Revenue by Type Instrumentation $ 632 $ 491 $ 1,313 $ 1,084 Non-instrumentation and other 893 747 1,760 1,511 Total $ 1,525 $ 1,238 $ 3,073 $ 2,595 Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue include sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services. Contract Balances Contract Assets Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet. The balances of contract assets as of April 30, 2021 and October 31, 2020 were $165 million and $153 million, respectively. The increase in unbilled receivables during the six months ended April 30, 2021 is a result of recognition of revenue upon the transfer of the control to the customer. Contract Liabilities The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2021: Contract (in millions) Ending balance as of October 31, 2020 $ 446 Net revenue deferred in the period 304 Revenue recognized that was included in the contract liability balance at the beginning of the period (267) Change in deferrals from customer cash advances, net of revenue recognized 7 Currency translation and other adjustments 7 Ending balance as of April 30, 2021 $ 497 During the six months ended April 30, 2020 revenue recognized that was included in the contract liability balance at October 31, 2019 was $226 million. Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Contract Costs Incremental costs of obtaining a contract with a customer are recognized as an asset if we expect the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the three and six months ended April 30, 2021 and was included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities. Transaction Price Allocated to the Remaining Performance Obligations We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less.

SHARE-BASED COMPENSATION (Notes

SHARE-BASED COMPENSATION (Notes)	6 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement, Noncash Expense [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION We account for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including employee stock options, restricted stock units, employee stock purchases made under our employee stock purchase plan and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values. We have two LTPP performance stock award programs, which are administered under the 2018 Stock Plan, for our executive officers and other key employees. Participants in our LTPP Total Stockholders’ Return (“TSR”) and LTPP Earnings Per Share (“EPS”) programs are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets for the programs are met. The LTPP-TSR awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the TSR set at the beginning of the performance period. The LTPP-EPS awards are based on the company’s EPS performance over a three-year period. The performance targets for the LTPP-EPS for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards are subject to a one-year post-vest holding period. The final LTPP award may vary from 0 percent to 200 percent of the target award. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. In fiscal year 2021, we resumed granting stock options. Stock options granted under the 2018 Stock Plan may be either "incentive stock options", as defined in Section 422 of the Internal Revenue Code, or non-statutory. Options generally vest at a rate of 25 percent per year over a period of four years from the date of grant with a maximum contractual term of ten years. The exercise price for stock options is generally not less than 100 percent of the fair market value of our common stock on the date the stock award is granted. We issue new shares of common stock when employee stock options are exercised. The impact on our results for share-based compensation was as follows: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Cost of products and services $ 6 $ 5 $ 15 $ 11 Research and development 2 2 6 5 Selling, general and administrative 19 11 46 29 Total share-based compensation expense $ 27 $ 18 $ 67 $ 45 At April 30, 2021 and October 31, 2020, there was no share-based compensation capitalized within inventory. The following assumptions were used to estimate the fair value of awards granted. Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 Stock Option Plans: Weighted average risk-free interest rate 0.9% — 0.5 % — Dividend yield 0.6% — 0.7 % — Weighted average volatility 26% — 26 % — Expected life 5.5 years — 5.5 years — LTPP: Volatility of Agilent shares 30% 23% 30% 23% Volatility of selected peer-company shares 24%-57% 15%-44% 24%-57% 15%-44% Pair-wise correlation with selected peers 45% 29% 45% 29% Post-vest holding restriction discount for all executive awards 6.8% 5.3% 6.8% 5.3% The fair value of share-based awards for our employee stock option awards was estimated using the Black-Scholes option pricing model. Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulation model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value. We use historical volatility to estimate the expected stock price volatility assumption for employee stock option awards. In reaching the conclusion, we have considered many factors including the extent to which our options are currently traded and our ability to find traded options in the current market with similar terms and prices to the options we are valuing. In estimating the expected life of our options granted we considered the historical option exercise behavior of our executives, which we believe is representative of future behavior. The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period.

INCOME TAXES (Notes)

INCOME TAXES (Notes)	6 Months Ended
	Apr. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three and six months ended April 30, 2021, our income tax expense was $57 million with an effective tax rate of 20.9 percent and $81 million with an effective tax rate of 13.8 percent, respectively. For the three months ended April 30, 2021, there were no significant discrete tax items. For the six months ended April 30, 2021, our effective tax rate and the resulting provision for income taxes were impacted by the expiration of various foreign statutes of limitations which resulted in the recognition of previously unrecognized tax benefits of $16 million. The income taxes for the six months ended April 30, 2021 also include the excess tax benefits from stock-based compensation of $22 million. Our calculation of income tax expense for the three and six months ended April 30, 2021 is dependent in part on forecasts of full year results. The impact of the COVID-19 outbreak on the economic environment is uncertain and may change these forecasts, which could impact tax expense. For the three and six months ended April 30, 2020, our income tax expense was $20 million with an effective tax rate of 16.5 percent and $42 million with an effective tax rate of 12.4 percent, respectively. For the three months ended April 30, 2020, there were no significant discrete tax items. For the six months ended April 30, 2020, our effective tax rate and the resulting provision for income taxes were impacted by a discrete tax benefit of $14 million related to the excess tax benefits from stock compensation. In the U.S., tax years remain open back to the year 2017 for federal income tax purposes and for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2009. With these jurisdictions and the U.S., it is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement which will be partially offset by an anticipated tax liability related to unremitted foreign earnings, where applicable. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits.

NET INCOME PER SHARE (Notes)

NET INCOME PER SHARE (Notes)	6 Months Ended
	Apr. 30, 2021
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Numerator: Net income $ 216 $ 101 $ 504 $ 298 Denominator: Basic weighted-average shares 304 309 305 310 Potential common shares— stock options and other employee stock plans 3 3 3 3 Diluted weighted-average shares 307 312 308 313 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive.

INVENTORY (Notes)

INVENTORY (Notes)	6 Months Ended
	Apr. 30, 2021
Inventory, Net [Abstract]
INVENTORY	INVENTORY Inventory as of April 30, 2021 and October 31, 2020 consisted of the following: April 30, October 31, (in millions) Finished goods $ 443 $ 417 Purchased parts and fabricated assemblies 348 303 Inventory $ 791 $ 720

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)	6 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2021: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2020 $ 1,441 $ 1,599 $ 562 $ 3,602 Foreign currency translation impact 9 3 5 17 Goodwill arising from acquisitions and adjustments — 435 — 435 Goodwill as of April 30, 2021 $ 1,450 $ 2,037 $ 567 $ 4,054 The component parts of other intangible assets as of April 30, 2021 and October 31, 2020 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2020 Purchased technology $ 1,429 $ 863 $ 566 Trademark/Tradename 196 117 79 Customer relationships 330 158 172 Third-party technology and licenses 11 7 4 Total amortizable intangible assets 1,966 1,145 821 In-Process R&D 10 — 10 Total $ 1,976 $ 1,145 $ 831 As of April 30, 2021 Purchased technology $ 1,661 $ 916 $ 745 Backlog 8 — 8 Trademark/Tradename 196 125 71 Customer relationships 360 193 167 Third-party technology and licenses 11 8 3 Total amortizable intangible assets 2,236 1,242 994 In-Process R&D 11 — 11 Total $ 2,247 $ 1,242 $ 1,005 On April 15, 2021 we completed the acquisition of privately-owned Resolution Bioscience, Inc., a biotechnology company focused on the development and commercialization of next-generation sequencing-based ("NGS") precision oncology solutions, for $550 million cash plus potential future contingent payments of up to $145 million upon the achievement of certain milestones which are based on certain revenue and technical targets. Resolution Bioscience complements and expands our capabilities in NGS-based cancer diagnostics and provides us with innovative technology to further serve the needs of the fast-growing precision medicine market. As a result of this acquisition, we recorded a short-term liability of $47 million in other accrued liabilities and a long-term liability of $49 million in other long-term liabilities on our condensed consolidated balance sheet which reflects the estimated fair value of the potential future contingent payments. We also recorded additions to goodwill of $435 million and additions to other intangible assets of $263 million during the six months ended April 30, 2021. Due to the timing of the close, the valuation of the tangible and intangible assets and related tax impacts and contingent consideration of this acquisition is preliminary and we anticipate will be completed by our fiscal year end. During the six months ended April 30, 2021, other intangible assets in total increased $1 million due to the impact of foreign currency translation. In general, for United States federal tax purposes, goodwill from asset purchases is deductible; however, any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and six months ended April 30, 2021 and 2020 we did not identify any triggering events or circumstances, including impacts due to COVID-19, which would indicate an impairment of goodwill. During the three and six months ended April 30, 2021, there were no indicators of impairments of indefinite-lived intangible assets. During the three and six months ended April 30, 2020, we recorded an impairment of in-process research and development of $90 million related to the shut-down of our sequencer development program in our diagnostics and genomics segment. Amortization expense of intangible assets was $45 million and $90 million for the three and six months ended April 30, 2021, respectively. Amortization expense of intangible assets was $47 million and $95 million for the three and six months ended April 30, 2020, respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2021 and for each of the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2021 $ 99 2022 $ 181 2023 $ 133 2024 $ 112 2025 $ 86 2026 $ 56 Thereafter $ 327

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	6 Months Ended
	Apr. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of April 30, 2021 were as follows: Fair Value Measurement at April 30, 2021 Using April 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 526 $ 526 $ — $ — Derivative instruments (foreign exchange contracts) 10 — 10 — Long-term Trading securities 33 33 — — Other investments 43 13 30 — Total assets measured at fair value $ 612 $ 572 $ 40 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 19 $ — $ 19 $ — Contingent consideration 47 — — 47 Long-term Deferred compensation liability 33 — 33 — Contingent consideration 49 — — 49 Total liabilities measured at fair value $ 148 $ — $ 52 $ 96 Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows: Fair Value Measurement at October 31, 2020 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 740 $ 740 $ — $ — Derivative instruments (foreign exchange contracts) 2 — 2 — Long-term Trading securities 30 30 — — Other investments 25 — 25 — Total assets measured at fair value $ 797 $ 770 $ 27 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 17 $ — $ 17 $ — Contingent consideration — — — — Long-term Deferred compensation liability 30 — 30 — Contingent consideration — — — — Total liabilities measured at fair value $ 47 $ — $ 47 $ — Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments includes shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. These shares have been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are or can be derived from and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself. Other investments also include shares in marketable equity securities and are classified as level 1 in the fair value hierarchy as they are measured based on quotes in active markets. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive income (loss) within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. For the three and six months ended April 30, 2021 and 2020, an unrealized gain of $11 million and zero, respectively, was included in net income as an adjustment to the carrying value of marketable equity securities. The preliminary fair value of the contingent consideration liability relates to milestone payments in connection with the April 2021 acquisition of Resolution Bioscience. The fair value of the potential future milestone payments, which are set to certain revenue and technical targets, was based on (i) the probability of achieving the relevant revenue targets and technical milestones and (ii) the timing of achieving such milestones, which are significant unobservable inputs, and has been classified as Level 3. We used the Monte Carlo simulation approach to estimate the fair value of the revenue component with an asset volatility of 54.9 percent and revenue volatilities ranging from 13.8 to 14 percent. The probability-weighted expected return method was used to estimate the fair value of the technical target component. A change in any of these unobservable inputs can significantly change the fair value of the contingent consideration. As of the date of the close, the fair value of the contingent consideration liability was estimated to be a total of $96 million of which $47 million is short-term and was recorded in other accrued liabilities and $49 million is long-term and was recorded in other long-term liabilities on the condensed consolidated balance sheet. There were no significant changes to this estimate at April 30, 2021. Impairment of Investments. There were no impairments of investments for the three and six months ended April 30, 2021 and 2020. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis For the three and six months ended April 30, 2021, long-lived assets held and used with a carrying amount of $2 million were written down to fair value of zero, resulting in an impairment of $2 million. For the three and six months ended April 30, 2020, long-lived assets held and used with a carrying amount of $98 million were written down to fair value of zero, resulting in an impairment of $98 million related to the shut-down of our sequencer development program in our diagnostics and genomics segment. For the three and six months ended April 30, 2021 and 2020, there were no impairments of long-lived assets held for sale. For the three and six months ended April 30, 2021 and 2020, there was no impairment of non-marketable securities. For the three months ended April 30, 2021 and 2020, an unrealized gain of zero and $11 million, respectively, was included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. For the six months ended April 30, 2021 and 2020, an unrealized gain of zero and $27 million, respectively, was included in net income as an adjustment to the carrying value of non-marketable equity securities without readily determinable fair value based on an observable market transaction. As of April 30, 2021 and October 31, 2020, the carrying amount of non-marketable equity securities without readily determinable fair values was $111 million and $103 million, respectively. Fair values for the non-marketable securities included in long-term investments on the condensed consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when they occur.

DERIVATIVES (Notes)

DERIVATIVES (Notes)	6 Months Ended
	Apr. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts and purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of April 30, 2021, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense), net in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense), net in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the three and six months ended April 30, 2021 and 2020, ineffectiveness and gains and losses recognized in other income (expense), net due to de-designation of cash flow hedge contracts were not significant. In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 13, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012, and we recognized a deferred gain in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2022 senior notes. On January 21, 2021 we redeemed $100 million of the $400 million aggregate principal amount of our 2022 senior notes. On April 5, 2021, we redeemed the remaining outstanding $300 million of our 2022 senior notes. We also recognized the remaining deferred gain on the terminated treasury lock related to the 2022 senior notes to other income (expense), net. For more information see Note 14, "Long-Term Debt". In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million, and we recognized this as a deferred loss in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at April 30, 2021 was $5 million. In August 2019, Agilent executed treasury lock agreements for $250 million in connection with future interest payments to be made on our 2029 senior notes issued on September 16, 2019. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 6, 2019, and we recognized a deferred loss of $6 million in accumulated other comprehensive income (loss) which is being amortized to interest expense over the life of the 2029 senior notes. The remaining loss to be amortized related to the treasury lock agreements at April 30, 2021 was $5 million. Net Investment Hedges Starting in 2020, we entered into foreign exchange contracts to hedge net investments in foreign operations to mitigate the risk of adverse movements in exchange rates. These foreign exchange contracts are carried at fair value and are designated and qualify as net investment hedges under the criteria prescribed in the authoritative guidance. Changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss) and are assessed for effectiveness against the underlying exposure every reporting period. If the company’s net investment changes during the year, the hedge relationship will be assessed and de-designated if the hedge notional amount is outside of prescribed tolerance with a gain/loss reclassified from other comprehensive income (loss) to other income (expense) in the current period. As of April 30, 2021, we have 3 open forward contracts to sell euros to buy USD maturing in the third quarter of fiscal year 2021, and these are designated as a net investment hedge of the U.S. parent's interest in foreign subsidiaries denominated in euro functional currency. In the three and six months ended April 30, 2021, the change in fair value of the net investment hedge resulted in a net gain of $1 million and a net loss of $3 million, respectively, recognized in accumulated other comprehensive income (loss) within foreign currency translation. For the three and six months ended April 30, 2021, ineffectiveness and the resultant effect of any gains or losses recognized in other income (expense) due to de-designation of the hedge contracts were not significant. Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense), net in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of April 30, 2021, was $15 million. The credit-risk-related contingent features underlying these agreements had not been triggered as of April 30, 2021. There were 270 foreign exchange forward contracts open as of April 30, 2021 and designated as cash flow hedges. There were 196 foreign exchange forward contracts open as of April 30, 2021 and not designated as hedging instruments. There were 3 foreign exchange forward contracts open as of April 30, 2021 and designated as a net investment hedge. The aggregated notional amounts by currency and designation as of April 30, 2021 were as follows: Derivatives Derivatives Derivatives Forward Forward Forward Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (77) $ (94) $ 31 British Pound (56) — (12) Canadian Dollar (40) — (20) Japanese Yen (98) — (33) Danish Krone — — 34 Korean Won (63) — (21) Singapore Dollar 15 — 18 Swiss Franc — — (5) Chinese Yuan Renminbi (97) — (38) Swedish Krona — — (11) Taiwan Dollar — — (9) Indian Rupee — — (13) Brazilian Real — — (6) Thai Baht — — (7) Other 4 — (2) Totals $ (412) $ (94) $ (94) Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the condensed consolidated balance sheet as of April 30, 2021 and October 31, 2020 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location April 30, October 31, 2020 Balance Sheet Location April 30, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 4 $ — Other accrued liabilities $ 10 $ 12 Net investment hedges Foreign exchange contracts Other current assets $ — $ — Other accrued liabilities $ 2 $ — Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 6 $ 2 Other accrued liabilities $ 7 $ 5 Total derivatives $ 10 $ 2 $ 19 $ 17 The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our condensed consolidated statement of operations were as follows: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss $ — $ 2 $ (6) $ 3 Loss reclassified from accumulated other comprehensive loss into interest expense $ — $ (1) $ — $ (1) Gain (loss) reclassified from accumulated other comprehensive loss into cost of sales $ (6) $ 2 $ (14) $ 2 Gain on time value of forward contracts recorded in cost of sales $ — $ 2 $ — $ 2 Net Investment Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss $ 1 $ 1 $ (3) $ 1 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ 3 $ (1) $ (1) $ (3)

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)	3 Months Ended
	Apr. 30, 2021
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Components of net periodic costs (benefits). For the three and six months ended April 30, 2021 and 2020, our net pension and post retirement benefit costs (benefits) were comprised of the following: Three Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2021 2020 2021 2020 2021 2020 (in millions) Service cost—benefits earned during the period $ — $ — $ 4 $ 5 $ — $ — Interest cost on benefit obligation 4 4 2 2 1 1 Expected return on plan assets (8) (7) (13) (12) (1) (2) Amortization: Actuarial losses 1 1 14 12 1 1 Prior service credits — — — — (1) (2) Total net plan costs (benefits) $ (3) $ (2) $ 7 $ 7 $ — $ (2) Six Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2021 2020 2021 2020 2021 2020 (in millions) Service cost—benefits earned during the period $ — $ — $ 11 $ 12 $ — $ — Interest cost on benefit obligation 7 8 4 4 2 2 Expected return on plan assets (15) (15) (25) (24) (3) (3) Amortization: Actuarial losses 2 2 27 24 2 2 Prior service credits — — — — (1) (4) Total net plan costs (benefits) $ (6) $ (5) $ 17 $ 16 $ — $ (3) The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations. Employer contributions and expected future employer contributions for the remainder of the year were as follows: Three Months Ended Six Months Ended Employer Contributions April 30, April 30, For Remainder of Year 2021 2020 2021 2020 2021 (in millions) U.S. defined benefit plans $ — $ — $ — $ — $ — Non-U.S. defined benefit plans $ 4 $ 14 $ 9 $ 19 $ 13

WARRANTIES AND CONTINGENCIES (N

WARRANTIES AND CONTINGENCIES (Notes)	6 Months Ended
	Apr. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
WARRANTIES AND CONTINGENCIES	WARRANTIES AND CONTINGENCIES Warranties We accrue for standard warranty costs based on historical trends in actual warranty charges over the past 12 months. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost over the period. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below: Six Months Ended April 30, 2021 2020 (in millions) Standard warranty accrual, beginning balance $ 32 $ 32 Accruals for warranties including change in estimates 26 25 Settlements made during the period (26) (27) Standard warranty accrual, ending balance $ 32 $ 30 Accruals for warranties due within one year $ 31 $ 30 Accruals for warranties due after one year 1 — Standard warranty accrual, ending balance $ 32 $ 30 Bank Guarantees Guarantees consist primarily of outstanding standby letters of credit and bank guarantees and were approximately $47 million as of April 30, 2021 and $43 million as of October 31, 2020. A standby letter of credit is a guarantee of payment issued by a bank on behalf of us that is used as payment of last resort should we fail to fulfill a contractual commitment with a third party. A bank guarantee is a promise from a bank or other lending institution that if we default on a loan, the bank will cover the loss. Contingencies We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are reasonably possible of having a material impact to our business, condensed consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT (Notes)

SHORT-TERM DEBT (Notes)	6 Months Ended
	Apr. 30, 2021
Short-term Debt [Abstract]
SHORT-TERM DEBT	SHORT-TERM DEBT Credit Facilities On March 13, 2019, we entered into a credit agreement with a group of financial institutions which, as amended, provided for a $1 billion five-year unsecured credit facility that will expire on March 13, 2024 and incremental term loan facilities in an aggregate amount of up to $500 million. On April 21, 2021, we entered into an incremental assumption agreement, pursuant to which the aggregate amount available for borrowing under the revolving credit facility was increased to $1.35 billion and the aggregate amount available for incremental facilities was refreshed to remain at $500 million. As of April 30, 2021, we had no borrowings outstanding under the credit facility and no borrowings under the incremental facilities. We were in compliance with the covenants for the credit facility during the six months ended April 30, 2021. Commercial Paper In May 2020, we established a U.S. commercial paper program, under which the company may issue and sell unsecured, short-term promissory notes in the aggregate principal amount not to exceed $1.0 billion with up to 397-day maturities. At any point in time, the company intends to maintain available commitments under its revolving credit facility in an amount at least equal to the amount of the commercial paper notes outstanding. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The proceeds from issuances under the program may be used for general corporate purposes. As of April 30, 2021

LONG-TERM DEBT (Notes)

LONG-TERM DEBT (Notes)	6 Months Ended
	Apr. 30, 2021
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Senior Notes The following table summarizes the company’s long-term senior notes: April 30, 2021 October 31, 2020 Amortized Amortized (in millions) 2022 Senior Notes $ — $ 400 2023 Senior Notes 599 598 2026 Senior Notes 298 298 2029 Senior Notes 494 493 2030 Senior Notes 495 495 2031 Senior Notes 841 — Total $ 2,727 $ 2,284 2022 Senior Notes On September 13, 2012, the company issued an aggregate principal amount of $400 million in senior notes ("2022 senior notes"). The 2022 senior notes were issued at 99.80% of their principal amount. The notes will mature on October 1, 2022, and bear interest at a fixed rate of 3.20% per annum. The interest is payable semi-annually on April 1st and October 1st of each year and payments commenced on April 1, 2013. On January 21, 2021, we redeemed $100 million of the $400 million outstanding aggregate principal amount of our 2022 senior notes due October 1, 2022. On April 5, 2021, we redeemed the remaining outstanding $300 million of our 2022 senior notes. The total redemption price of approximately $417 million was computed in accordance with the terms of the 2022 senior notes as the present value of the remaining scheduled payments of principal and unpaid interest on the notes being redeemed. During the three and six months ended April 30, 2021, we recorded a loss on extinguishment of debt of $12 million and $17 million, respectively, in other income (expense), net in the condensed consolidated statement of operations. In addition, $1 million of accrued interest, up to but not including the applicable redemption date, was paid. The make-whole premium less partial amortization of previously deferred interest rate swap gain together with the amortization of debt issuance costs and discount was recorded in other income (expense), net in the condensed consolidated statement of operations. 2031 Senior Notes On March 12, 2021, we issued an aggregate principal amount of $850 million in senior notes ("2031 senior notes"). The 2031 senior notes were issued at 99.822% of their principal amount. The 2031 senior notes will mature on March 12, 2031, and bear interest at a fixed rate of 2.30% per annum. The interest is payable semi-annually on March 12th and September 12th of each year and payments commence on September 12, 2021.

STOCKHOLDERS' EQUITY (Notes)

STOCKHOLDERS' EQUITY (Notes)	6 Months Ended
	Apr. 30, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	STOCKHOLDERS' EQUITY Stock Repurchase Program On November 19, 2018 we announced that our board of directors had approved a share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three and six months ended April 30, 2021, we repurchased and retired 164,422 shares for $21 million and 3.050 million shares for $365 million, respectively, under this authorization. During the three and six months ended April 30, 2020, we repurchased and retired 1.663 million shares for $126 million and 2.389 million shares for $186 million, respectively, under this authorization. Effective February 18, 2021, the 2019 repurchase program was terminated and replaced by the new share repurchase program. The remaining authorization under the 2019 repurchase plan of $193 million expired on February 18, 2021. On February 16, 2021 we announced that our board of directors had approved a new share repurchase program (the "2021 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2021 repurchase program authorizes the purchase of up to $2.0 billion of our common stock at the company's discretion and has no fixed termination date. The 2021 repurchase program which became effective on February 18, 2021, replaced and terminated the 2019 repurchase program on that date. The 2021 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During both the three and six months ended April 30, 2021, we repurchased and retired 1.388 million shares for $174 million under this authorization. As of April 30, 2021, we had remaining authorization to repurchase up to approximately $1.826 billion of our common stock under this program. Cash Dividends on Shares of Common Stock During the three and six months ended April 30, 2021, we paid cash dividends of $0.194 per common share or $59 million and $0.388 per common share or $118 million, respectively, on the company's common stock. During the three and six months ended April 30, 2020, we paid cash dividends of $0.180 per common share or $55 million and $0.360 per common share or $111 million on the company's common stock. On May 19, 2021, our board of directors declared a quarterly dividend of $0.194 per share of common stock or approximately $59 million which will be paid on July 28, 2021 to all shareholders of record at the close of business on July 6, 2021. The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended April 30, 2021 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of January 31, 2021 $ (152) $ 125 $ (433) $ (9) $ (469) Other comprehensive income (loss) before reclassifications 2 — — — 2 Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 16 6 21 Tax (expense) benefit — — (4) (2) (6) Other comprehensive income (loss) 2 (1) 12 4 17 As of April 30, 2021 $ (150) $ 124 $ (421) $ (5) $ (452) Six Months Ended April 30, 2021 As of October 31, 2020 $ (194) $ 125 $ (442) $ (11) $ (522) Other comprehensive income (loss) before reclassifications 44 — (3) (6) 35 Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 32 14 45 Tax (expense) benefit — — (8) (2) (10) Other comprehensive income (loss) 44 (1) 21 6 70 As of April 30, 2021 $ (150) $ 124 $ (421) $ (5) $ (452) Reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended April 30, 2021 and 2020 were as follows (in millions): Details about accumulated other Amounts Reclassified from Affected line item in Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 Unrealized gain (loss) on derivatives $ (6) $ 2 $ (14) $ 2 Cost of products — (1) — (1) Interest expense (6) 1 (14) 1 Total before income tax 2 — 4 — Provision for income tax (4) 1 (10) 1 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (16) (14) (32) (28) Prior service benefit 1 2 1 4 (15) (12) (31) (24) Total before income tax 4 2 8 8 Benefit for income tax (11) (10) (23) (16) Total net of income tax Total reclassifications for the period $ (15) $ (9) $ (33) $ (15) Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss). Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost (see Note 11, "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION (Notes)

SEGMENT INFORMATION (Notes)	6 Months Ended
	Apr. 30, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry ("MP-AES") instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry ("IHC"), in situ hybridization ("ISH"), hematoxylin and eosin ("H&E") staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential tissue and liquid-based pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, facilities, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization of acquisition-related intangible assets, transformational initiatives expenses, acquisition and integration costs, business exit and divestiture costs, asset impairments and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations and in-sourcing or outsourcing of activities. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Net Revenue: Life Sciences and Applied Markets $ 674 $ 526 $ 1,396 $ 1,164 Diagnostics and Genomics 315 263 609 512 Agilent CrossLab 536 449 1,068 919 Total net revenue $ 1,525 $ 1,238 $ 3,073 $ 2,595 Segment Income From Operations: Life Sciences and Applied Markets $ 154 $ 98 $ 353 $ 256 Diagnostics and Genomics 69 57 124 91 Agilent CrossLab 141 122 283 241 Total segment income from operations $ 364 $ 277 $ 760 $ 588 The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Total segment income from operations $ 364 $ 277 $ 760 $ 588 Transformational initiatives (9) (15) (20) (28) Amortization of intangible assets related to business combinations (46) (46) (90) (94) Acquisition and integration costs (13) (11) (22) (24) Asset impairment (2) (99) (2) (99) Business exit and divestiture costs (3) — (4) — Other (1) (3) (4) (6) (26) Interest income 1 3 1 6 Interest expense (20) (20) (39) (40) Other income (expense), net (2) 4 36 7 57 Income before taxes, as reported $ 273 $ 121 $ 585 $ 340 (1) For the six months ended April 30, 2020, the other category primarily includes the legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments. (2) For the three and six months ended April 30, 2020 other income (expense), net includes the settlement of the legal claim against Twist Bioscience Corporation. The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. April 30, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 3,119 $ 3,143 Diagnostics and Genomics 3,262 2,515 Agilent CrossLab 1,425 1,375 Total segment assets $ 7,806 $ 7,033

OVERVIEW, BASIS OF PRESENTATI_2

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Apr. 30, 2021
Accounting Policies [Abstract]
Overview and Basis of Presentation	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2021 and 2020 pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2020 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2020. In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2021 and October 31, 2020, condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2021 and 2020, condensed consolidated statement of operations for the three and six months ended April 30, 2021 and 2020, condensed consolidated statement of cash flows for the six months ended April 30, 2021 and 2020 and condensed consolidated statement of equity for the three and six months ended April 30, 2021 and 2020.
Use of Estimates	Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, retirement and post-retirement benefit plan assumptions, valuation of goodwill and purchased intangible assets and accounting for income taxes.
Restricted Cash and Restricted Cash Equivalents	Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: April 30, October 31 2021 2020 (in millions) Cash and cash equivalents $ 1,380 $ 1,441 Restricted cash included in other assets 7 6 Total cash, cash equivalents and restricted cash $ 1,387 $ 1,447
Leases	Leases. As of April 30, 2021 and October 31, 2020, operating lease right-of-use assets where we are the lessee were $186 million and $175 million, respectively, and were included within other assets in the accompanying condensed consolidated balance sheet. The associated operating lease liabilities were $191 million and $178 million as of April 30, 2021 and October 31, 2020, respectively, and were included in other accrued liabilities and other long-term liabilities in the accompanying condensed consolidated balance sheet.
Variable Interest Entity	Variable Interest Entities. We make a determination upon entering into an arrangement whether an entity in which we have made an investment is considered a Variable Interest Entity (“VIE”). We evaluate our investments in privately held companies on an ongoing basis. We have determined that as of April 30, 2021 and October 31, 2020, there were no VIEs required to be consolidated in our consolidated financial statements because we do not have a controlling financial interest in any of the VIEs in which we have invested nor are we the primary beneficiary. We account for these investments under either the equity method or as equity investments without readily determinable fair value, depending on the circumstances. We periodically reassess whether we are the primary beneficiary of a VIE. The reassessment process considers whether we have acquired the power to direct the most significant activities of the VIE through changes in governing documents or other circumstances. We also reconsider whether entities previously determined not to be VIEs have become VIEs and vice-versa, based on changes in facts and circumstances including changes in contractual arrangements and capital structure. As of April 30, 2021 and October 31, 2020, the total carrying value of investments and loans in privately held companies considered as VIEs was $53 million and $67 million respectively. The maximum exposure is equal to the carrying value because we do not have future funding commitments. The investments are included on the long-term investments line and the loans on the other current assets and other assets lines (depending upon tenure of loan) on the condensed consolidated balance sheet.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy exceeds the carrying value by approximately $79 million and $162 million as of April 30, 2021 and October 31, 2020, respectively. The fair value is greater than carrying value primarily due to decreased market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs (for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies) are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments and contingent consideration.

OVERVIEW, BASIS OF PRESENTATI_3

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Apr. 30, 2021
Restricted Cash [Abstract]
Restrictions on Cash and Cash Equivalents	Restricted Cash and Restricted Cash Equivalents. Restricted cash and restricted cash equivalents are included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: April 30, October 31 2021 2020 (in millions) Cash and cash equivalents $ 1,380 $ 1,441 Restricted cash included in other assets 7 6 Total cash, cash equivalents and restricted cash $ 1,387 $ 1,447

REVENUE (Tables)

REVENUE (Tables)	6 Months Ended
	Apr. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Three Months Ended April 30, 2021 2020 Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Revenue by Region Americas $ 231 $ 187 $ 163 $ 581 $ 170 $ 161 $ 126 $ 457 Europe 155 154 106 415 111 131 92 334 Asia Pacific 288 195 46 529 245 157 45 447 Total $ 674 $ 536 $ 315 $ 1,525 $ 526 $ 449 $ 263 $ 1,238 Six Months Ended April 30, 2021 2020 Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total Life Sciences and Applied Markets Agilent CrossLab Diagnostics and Genomics Total (in millions) Revenue by Region Americas $ 455 $ 366 $ 315 $ 1,136 $ 379 $ 328 $ 244 $ 951 Europe 345 301 206 852 278 264 184 726 Asia Pacific 596 401 88 1,085 507 327 84 918 Total $ 1,396 $ 1,068 $ 609 $ 3,073 $ 1,164 $ 919 $ 512 $ 2,595 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Revenue by End Markets Pharmaceutical and Biopharmaceutical $ 531 $ 400 $ 1,052 $ 823 Chemical and Energy 314 267 642 579 Diagnostics and Clinical 233 200 449 394 Food 144 114 306 244 Academia and Government 143 115 285 256 Environmental and Forensics 160 142 339 299 Total $ 1,525 $ 1,238 $ 3,073 $ 2,595 Revenue by Type Instrumentation $ 632 $ 491 $ 1,313 $ 1,084 Non-instrumentation and other 893 747 1,760 1,511 Total $ 1,525 $ 1,238 $ 3,073 $ 2,595
Contract Liabilities and Changes in Balances	The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2021: Contract (in millions) Ending balance as of October 31, 2020 $ 446 Net revenue deferred in the period 304 Revenue recognized that was included in the contract liability balance at the beginning of the period (267) Change in deferrals from customer cash advances, net of revenue recognized 7 Currency translation and other adjustments 7 Ending balance as of April 30, 2021 $ 497

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Apr. 30, 2021
Share-based Payment Arrangement, Noncash Expense [Abstract]
Allocated share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Cost of products and services $ 6 $ 5 $ 15 $ 11 Research and development 2 2 6 5 Selling, general and administrative 19 11 46 29 Total share-based compensation expense $ 27 $ 18 $ 67 $ 45
Assumptions used to estimate fair value for LTPP	The following assumptions were used to estimate the fair value of awards granted. Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 Stock Option Plans: Weighted average risk-free interest rate 0.9% — 0.5 % — Dividend yield 0.6% — 0.7 % — Weighted average volatility 26% — 26 % — Expected life 5.5 years — 5.5 years — LTPP: Volatility of Agilent shares 30% 23% 30% 23% Volatility of selected peer-company shares 24%-57% 15%-44% 24%-57% 15%-44% Pair-wise correlation with selected peers 45% 29% 45% 29% Post-vest holding restriction discount for all executive awards 6.8% 5.3% 6.8% 5.3%

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	6 Months Ended
	Apr. 30, 2021
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Numerator: Net income $ 216 $ 101 $ 504 $ 298 Denominator: Basic weighted-average shares 304 309 305 310 Potential common shares— stock options and other employee stock plans 3 3 3 3 Diluted weighted-average shares 307 312 308 313

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Apr. 30, 2021
Inventory, Net [Abstract]
INVENTORY	INVENTORY Inventory as of April 30, 2021 and October 31, 2020 consisted of the following: April 30, October 31, (in millions) Finished goods $ 443 $ 417 Purchased parts and fabricated assemblies 348 303 Inventory $ 791 $ 720

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Apr. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segment during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2021: Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2020 $ 1,441 $ 1,599 $ 562 $ 3,602 Foreign currency translation impact 9 3 5 17 Goodwill arising from acquisitions and adjustments — 435 — 435 Goodwill as of April 30, 2021 $ 1,450 $ 2,037 $ 567 $ 4,054
Components of other intangible assets during the period	The component parts of other intangible assets as of April 30, 2021 and October 31, 2020 are shown in the table below: Other Intangible Assets Gross Accumulated Net Book (in millions) As of October 31, 2020 Purchased technology $ 1,429 $ 863 $ 566 Trademark/Tradename 196 117 79 Customer relationships 330 158 172 Third-party technology and licenses 11 7 4 Total amortizable intangible assets 1,966 1,145 821 In-Process R&D 10 — 10 Total $ 1,976 $ 1,145 $ 831 As of April 30, 2021 Purchased technology $ 1,661 $ 916 $ 745 Backlog 8 — 8 Trademark/Tradename 196 125 71 Customer relationships 360 193 167 Third-party technology and licenses 11 8 3 Total amortizable intangible assets 2,236 1,242 994 In-Process R&D 11 — 11 Total $ 2,247 $ 1,242 $ 1,005
Schedule of estimated future amortization expense of finite-lived intangible assets	Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2021 and for each of the next five fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2021 $ 99 2022 $ 181 2023 $ 133 2024 $ 112 2025 $ 86 2026 $ 56 Thereafter $ 327

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Apr. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of April 30, 2021 were as follows: Fair Value Measurement at April 30, 2021 Using April 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 526 $ 526 $ — $ — Derivative instruments (foreign exchange contracts) 10 — 10 — Long-term Trading securities 33 33 — — Other investments 43 13 30 — Total assets measured at fair value $ 612 $ 572 $ 40 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 19 $ — $ 19 $ — Contingent consideration 47 — — 47 Long-term Deferred compensation liability 33 — 33 — Contingent consideration 49 — — 49 Total liabilities measured at fair value $ 148 $ — $ 52 $ 96 Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2020 were as follows: Fair Value Measurement at October 31, 2020 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 740 $ 740 $ — $ — Derivative instruments (foreign exchange contracts) 2 — 2 — Long-term Trading securities 30 30 — — Other investments 25 — 25 — Total assets measured at fair value $ 797 $ 770 $ 27 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 17 $ — $ 17 $ — Contingent consideration — — — — Long-term Deferred compensation liability 30 — 30 — Contingent consideration — — — — Total liabilities measured at fair value $ 47 $ — $ 47 $ —

DERIVATIVES (Tables)

DERIVATIVES (Tables)	6 Months Ended
	Apr. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of April 30, 2021 were as follows: Derivatives Derivatives Derivatives Forward Forward Forward Currency Buy/(Sell) Buy/(Sell) Buy/(Sell) (in millions) Euro $ (77) $ (94) $ 31 British Pound (56) — (12) Canadian Dollar (40) — (20) Japanese Yen (98) — (33) Danish Krone — — 34 Korean Won (63) — (21) Singapore Dollar 15 — 18 Swiss Franc — — (5) Chinese Yuan Renminbi (97) — (38) Swedish Krona — — (11) Taiwan Dollar — — (9) Indian Rupee — — (13) Brazilian Real — — (6) Thai Baht — — (7) Other 4 — (2) Totals $ (412) $ (94) $ (94)
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the condensed consolidated balance sheet as of April 30, 2021 and October 31, 2020 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location April 30, October 31, 2020 Balance Sheet Location April 30, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 4 $ — Other accrued liabilities $ 10 $ 12 Net investment hedges Foreign exchange contracts Other current assets $ — $ — Other accrued liabilities $ 2 $ — Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 6 $ 2 Other accrued liabilities $ 7 $ 5 Total derivatives $ 10 $ 2 $ 19 $ 17
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effects of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our condensed consolidated statement of operations were as follows: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss $ — $ 2 $ (6) $ 3 Loss reclassified from accumulated other comprehensive loss into interest expense $ — $ (1) $ — $ (1) Gain (loss) reclassified from accumulated other comprehensive loss into cost of sales $ (6) $ 2 $ (14) $ 2 Gain on time value of forward contracts recorded in cost of sales $ — $ 2 $ — $ 2 Net Investment Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive loss $ 1 $ 1 $ (3) $ 1 Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ 3 $ (1) $ (1) $ (3)

RETIREMENT PLANS AND POST RET_2

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	6 Months Ended
	Apr. 30, 2021
Defined Benefit Plan, Net Periodic Benefit Cost
Schedule of net pension and post-retirement benefit costs	Components of net periodic costs (benefits). For the three and six months ended April 30, 2021 and 2020, our net pension and post retirement benefit costs (benefits) were comprised of the following: Three Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2021 2020 2021 2020 2021 2020 (in millions) Service cost—benefits earned during the period $ — $ — $ 4 $ 5 $ — $ — Interest cost on benefit obligation 4 4 2 2 1 1 Expected return on plan assets (8) (7) (13) (12) (1) (2) Amortization: Actuarial losses 1 1 14 12 1 1 Prior service credits — — — — (1) (2) Total net plan costs (benefits) $ (3) $ (2) $ 7 $ 7 $ — $ (2) Six Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2021 2020 2021 2020 2021 2020 (in millions) Service cost—benefits earned during the period $ — $ — $ 11 $ 12 $ — $ — Interest cost on benefit obligation 7 8 4 4 2 2 Expected return on plan assets (15) (15) (25) (24) (3) (3) Amortization: Actuarial losses 2 2 27 24 2 2 Prior service credits — — — — (1) (4) Total net plan costs (benefits) $ (6) $ (5) $ 17 $ 16 $ — $ (3) The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations.
Employer Contributions and Expected Employer Contributions	Employer contributions and expected future employer contributions for the remainder of the year were as follows: Three Months Ended Six Months Ended Employer Contributions April 30, April 30, For Remainder of Year 2021 2020 2021 2020 2021 (in millions) U.S. defined benefit plans $ — $ — $ — $ — $ — Non-U.S. defined benefit plans $ 4 $ 14 $ 9 $ 19 $ 13

WARRANTIES AND CONTINGENCIES (T

WARRANTIES AND CONTINGENCIES (Table)	6 Months Ended
	Apr. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Standard warranty	A summary of the standard warranty accrual activity is shown in the table below: Six Months Ended April 30, 2021 2020 (in millions) Standard warranty accrual, beginning balance $ 32 $ 32 Accruals for warranties including change in estimates 26 25 Settlements made during the period (26) (27) Standard warranty accrual, ending balance $ 32 $ 30 Accruals for warranties due within one year $ 31 $ 30 Accruals for warranties due after one year 1 — Standard warranty accrual, ending balance $ 32 $ 30

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	6 Months Ended
	Apr. 30, 2021
Debt Disclosure [Abstract]
Schedule of Senior Notes and Related Interest Rate Swaps	The following table summarizes the company’s long-term senior notes: April 30, 2021 October 31, 2020 Amortized Amortized (in millions) 2022 Senior Notes $ — $ 400 2023 Senior Notes 599 598 2026 Senior Notes 298 298 2029 Senior Notes 494 493 2030 Senior Notes 495 495 2031 Senior Notes 841 — Total $ 2,727 $ 2,284

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Apr. 30, 2021
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended April 30, 2021 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of January 31, 2021 $ (152) $ 125 $ (433) $ (9) $ (469) Other comprehensive income (loss) before reclassifications 2 — — — 2 Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 16 6 21 Tax (expense) benefit — — (4) (2) (6) Other comprehensive income (loss) 2 (1) 12 4 17 As of April 30, 2021 $ (150) $ 124 $ (421) $ (5) $ (452) Six Months Ended April 30, 2021 As of October 31, 2020 $ (194) $ 125 $ (442) $ (11) $ (522) Other comprehensive income (loss) before reclassifications 44 — (3) (6) 35 Amounts reclassified out of accumulated other comprehensive income (loss) — (1) 32 14 45 Tax (expense) benefit — — (8) (2) (10) Other comprehensive income (loss) 44 (1) 21 6 70 As of April 30, 2021 $ (150) $ 124 $ (421) $ (5) $ (452)
Reclassification out of Accumulated Other Comprehensive Income	Reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended April 30, 2021 and 2020 were as follows (in millions): Details about accumulated other Amounts Reclassified from Affected line item in Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 Unrealized gain (loss) on derivatives $ (6) $ 2 $ (14) $ 2 Cost of products — (1) — (1) Interest expense (6) 1 (14) 1 Total before income tax 2 — 4 — Provision for income tax (4) 1 (10) 1 Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (16) (14) (32) (28) Prior service benefit 1 2 1 4 (15) (12) (31) (24) Total before income tax 4 2 8 8 Benefit for income tax (11) (10) (23) (16) Total net of income tax Total reclassifications for the period $ (15) $ (9) $ (33) $ (15)

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2021
Segment Reporting [Abstract]
Segment Profitability and Segment Assets	The profitability of each of the segments is measured after excluding items such as transformational initiatives, acquisition and integration costs, amortization of intangible assets related to business combinations, interest income, interest expense and other items as noted in the reconciliations below: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Net Revenue: Life Sciences and Applied Markets $ 674 $ 526 $ 1,396 $ 1,164 Diagnostics and Genomics 315 263 609 512 Agilent CrossLab 536 449 1,068 919 Total net revenue $ 1,525 $ 1,238 $ 3,073 $ 2,595 Segment Income From Operations: Life Sciences and Applied Markets $ 154 $ 98 $ 353 $ 256 Diagnostics and Genomics 69 57 124 91 Agilent CrossLab 141 122 283 241 Total segment income from operations $ 364 $ 277 $ 760 $ 588 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. April 30, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 3,119 $ 3,143 Diagnostics and Genomics 3,262 2,515 Agilent CrossLab 1,425 1,375 Total segment assets $ 7,806 $ 7,033
Reconciliation of segment results to total enterprise results	The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Six Months Ended April 30, April 30, 2021 2020 2021 2020 (in millions) Total segment income from operations $ 364 $ 277 $ 760 $ 588 Transformational initiatives (9) (15) (20) (28) Amortization of intangible assets related to business combinations (46) (46) (90) (94) Acquisition and integration costs (13) (11) (22) (24) Asset impairment (2) (99) (2) (99) Business exit and divestiture costs (3) — (4) — Other (1) (3) (4) (6) (26) Interest income 1 3 1 6 Interest expense (20) (20) (39) (40) Other income (expense), net (2) 4 36 7 57 Income before taxes, as reported $ 273 $ 121 $ 585 $ 340 (1) For the six months ended April 30, 2020, the other category primarily includes the legal costs related to a claim we pursued against Twist Bioscience Corporation in addition to other miscellaneous adjustments. (2) For the three and six months ended April 30, 2020 other income (expense), net includes the settlement of the legal claim against Twist Bioscience Corporation.

OVERVIEW, BASIS OF PRESENTATI_4

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020	Apr. 30, 2020	Oct. 31, 2019
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Cash and cash equivalents	$ 1,380	$ 1,441
Restricted Cash	7	6
Cash, cash equivalents, restricted cash and restricted cash equivalents	1,387	1,447	$ 1,329	$ 1,388
Variable Interest Entity
Assets	10,398	9,627
Fair Value of Financial Instruments
Fair value of senior notes in excess of carrying value	79	162
Variable Interest Entity, Not Primary Beneficiary [Member]
Variable Interest Entity
Assets	53	67
Other Assets
Operating Leases
Right-of-Use Asset	186	175
Other accrued and long-term liabilities
Operating Leases
Present value of future minimum lease payments	$ 191	$ 178

REVENUE- Revenue by Region (Det

REVENUE- Revenue by Region (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Net revenue	$ 1,525	$ 1,238	$ 3,073	$ 2,595
Life Sciences and Applied Markets
Net revenue	674	526	1,396	1,164
Agilent CrossLab
Net revenue	536	449	1,068	919
Diagnostics and Genomics
Net revenue	315	263	609	512
Americas
Net revenue	581	457	1,136	951
Americas | Life Sciences and Applied Markets
Net revenue	231	170	455	379
Americas | Agilent CrossLab
Net revenue	187	161	366	328
Americas | Diagnostics and Genomics
Net revenue	163	126	315	244
Europe
Net revenue	415	334	852	726
Europe | Life Sciences and Applied Markets
Net revenue	155	111	345	278
Europe | Agilent CrossLab
Net revenue	154	131	301	264
Europe | Diagnostics and Genomics
Net revenue	106	92	206	184
Asia Pacific
Net revenue	529	447	1,085	918
Asia Pacific | Life Sciences and Applied Markets
Net revenue	288	245	596	507
Asia Pacific | Agilent CrossLab
Net revenue	195	157	401	327
Asia Pacific | Diagnostics and Genomics
Net revenue	$ 46	$ 45	$ 88	$ 84

REVENUE - Revenue by End Market

REVENUE - Revenue by End Markets (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Net revenue	$ 1,525	$ 1,238	$ 3,073	$ 2,595
Pharmaceutical and Biopharmaceutical
Net revenue	531	400	1,052	823
Chemical and Energy
Net revenue	314	267	642	579
Diagnostics and Clinical
Net revenue	233	200	449	394
Food
Net revenue	144	114	306	244
Academia and Government
Net revenue	143	115	285	256
Environmental and Forensics
Net revenue	$ 160	$ 142	$ 339	$ 299

REVENUE - Revenue by Type (Deta

REVENUE - Revenue by Type (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Net revenue	$ 1,525	$ 1,238	$ 3,073	$ 2,595
Instrumentation
Net revenue	632	491	1,313	1,084
Non-Instrumentation and Other
Net revenue	$ 893	$ 747	$ 1,760	$ 1,511

REVENUE - Contract Assets and L

REVENUE - Contract Assets and Liability (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Contract Asset
Contract Assets (Unbilled Accounts Receivable)	$ 165		$ 153
Contract Liability
Contract liability ending balance as of October 31, 2019	446
Net revenue deferred in the period	304
Revenue recognized that was included in the contract liability balance at the beginning of the period	(267)	$ 226
Change in deferrals from customer cash advances, net of revenue recognized	7
Currency Translation and Other Adjustment	7
Contract liability ending balance as of April 30, 2020	$ 497

REVENUE - Remaining Performance

REVENUE - Remaining Performance Obligation (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-04-30 $ in Millions	Apr. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation expected timing of satisfaction period	12 months
Remaining performance obligation amount	$ 228

SHARE-BASED COMPENSATION Text (

SHARE-BASED COMPENSATION Text (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended	12 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Oct. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award
ESPP plan purchase price (in hundredths)	85.00%	85.00%
Inventory
Share-based Compensation Arrangement by Share-based Payment Award
Share-based compensation capitalized in inventory			$ 0	$ 0
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage			25.00%
Vesting Period			4 years
Share Based Compensation Arrangement By Share Based Payment Award Award Maximum Contractual Term			ten years
Share Based Compensation Arrangement By Share Based Payment Award Incentive Compensation Plan Percent Of Market Price			100.00%
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage			25.00%
Vesting Period			4 years
Minimum | Performance Shares [LTPP]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage			0.00%
Maximum | Performance Shares [LTPP]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage			200.00%

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	$ 27	$ 18	$ 67	$ 45
Cost of Products and Services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	6	5	15	11
Research and Development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	2	2	6	5
Selling, General and Administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs
Share-based compensation expense	$ 19	$ 11	$ 46	$ 29

SHARE-BASED COMPENSATION Fair V

SHARE-BASED COMPENSATION Fair Value Assumptions (Details)	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.90%	0.00%	0.50%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.60%	0.00%	0.70%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	26.00%	0.00%	26.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	5 years 6 months		5 years 6 months
LTPP
Share-based Compensation Arrangement by Share-based Payment Award
Volatility of Agilent shares	30.00%	23.00%	30.00%	23.00%
Volatility of selected peer-company shares - Minimum	24.00%	15.00%	24.00%	15.00%
Volatility of selected peer-company shares - Maximum	57.00%	44.00%	57.00%	44.00%
Pair-wise correlation with selected peers (in hundredths)	45.00%	29.00%	45.00%	29.00%
LTPP & RSU
Share-based Compensation Arrangement by Share-based Payment Award
Discount for post-vesting restrictions	6.80%	5.30%	6.80%	5.30%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Income Tax Disclosure
Provision (benefit) for income taxes	$ 57	$ 20	$ 81	$ 42
Effective income tax rate	20.90%	16.50%	13.80%	12.40%
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations			$ 16
Excess tax benefit from stock based compensation			$ (22)	$ (14)

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Numerator:
Net income	$ 216	$ 101	$ 504	$ 298
Denominators:
Basic weighted-average shares	304	309	305	310
Potential common shares - stock options and other employee stock plans	3	3	3	3
Diluted weighted average shares	307	312	308	313
Anti-dilutive shares excluded from computation of dilutive earnings per share (in shares)	0	0	0	0

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Inventory, Net [Abstract]
Finished goods	$ 443	$ 417
Purchased parts and fabricated assemblies	348	303
Inventory	$ 791	$ 720

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) $ in Millions	6 Months Ended
	Apr. 30, 2021USD ($)
Goodwill Roll Forward
Goodwill beginning balance	$ 3,602
Foreign currency translation impact	17
Goodwill arising from acquisitions	435
Goodwill ending balance	4,054
Life Sciences and Applied Markets
Goodwill Roll Forward
Goodwill beginning balance	1,441
Foreign currency translation impact	9
Goodwill arising from acquisitions	0
Goodwill ending balance	1,450
Diagnostics and Genomics
Goodwill Roll Forward
Goodwill beginning balance	1,599
Foreign currency translation impact	3
Goodwill arising from acquisitions	435
Goodwill ending balance	2,037
Agilent CrossLab
Goodwill Roll Forward
Goodwill beginning balance	562
Foreign currency translation impact	5
Goodwill arising from acquisitions	0
Goodwill ending balance	$ 567

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Finite-Lived Intangible Assets, Net
Total Intangible Assets	$ 2,247	$ 1,976
Accumulated Amortization	1,242	1,145
Net Book Value	1,005	831
Purchased Technology
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1,661	1,429
Accumulated Amortization	916	863
Net Book Value	745	566
Backlog
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	8
Accumulated Amortization	0
Net Book Value	8
Trademark/Tradenames
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	196	196
Accumulated Amortization	125	117
Net Book Value	71	79
Customer Relationships
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	360	330
Accumulated Amortization	193	158
Net Book Value	167	172
Third-Party Technology and Licenses
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	11	11
Accumulated Amortization	8	7
Net Book Value	3	4
Total amortizable intangible assets
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	2,236	1,966
Accumulated Amortization	1,242	1,145
Finite-Lived Intangible Assets, Net	994	821
In-Process R&D
Indefinite-Lived Intangible Assets (Excluding Goodwill)
In-Process R&D	$ 11	$ 10

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($) $ in Millions	Apr. 15, 2021	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Finite-Lived Intangible Assets
Additions to goodwill				$ 435
Foreign currency translation impact on other intangible assets				1
Impairment of IPR&D		$ 0	$ 90	0	$ 90
Goodwill impairment		0	0	0	0
Amortization of intangible assets during the period		45	$ 47	90	$ 95
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		96		96
Other accrued liabilities | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		47		47		$ 0
Other accrued liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability						0
Other long-term liabilities | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		49		49		0
Other long-term liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability						$ 0
Life Sciences and Applied Markets
Finite-Lived Intangible Assets
Additions to goodwill				0
Diagnostics and Genomics
Finite-Lived Intangible Assets
Additions to goodwill				435
Resolution Bioscience, Inc.
Finite-Lived Intangible Assets
Additions to goodwill				435
Addition to other intangible assets				263
Acquisition
Purchase Price	$ 550
Contingent Consideration	$ 145
Resolution Bioscience, Inc. | Other accrued liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		47		47
Resolution Bioscience, Inc. | Other long-term liabilities | Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Acquisition
Contingent consideration liability		$ 49		$ 49

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) $ in Millions	Apr. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 99
2022	181
2023	133
2024	112
2025	86
2026	56
Thereafter	$ 327

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Assets, Long-term
Total assets measured at fair value	$ 612	$ 797
Liabilities Long-term
Total liabilities measured at fair value	148	47
Other Current Assets
Assets Short - term
Cash equivalents (money market funds)	526	740
Derivative instruments (foreign exchange contracts)	10	2
Other assets
Assets, Long-term
Trading securities	33	30
Other investments	43	25
Other accrued liabilities
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	19	17
Liabilities Long-term
Contingent consideration liability	47	0
Other long-term liabilities
Liabilities Long-term
Deferred compensation liability	33	30
Contingent consideration liability	49	0
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets, Long-term
Total assets measured at fair value	572	770
Liabilities Long-term
Total liabilities measured at fair value	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets
Assets Short - term
Cash equivalents (money market funds)	526	740
Derivative instruments (foreign exchange contracts)	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets
Assets, Long-term
Trading securities	33	30
Other investments	13	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	0	0
Liabilities Long-term
Contingent consideration liability	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities
Liabilities Long-term
Deferred compensation liability	0	0
Contingent consideration liability	0	0
Significant Other Observable Inputs (Level 2)
Assets, Long-term
Total assets measured at fair value	40	27
Liabilities Long-term
Total liabilities measured at fair value	52	47
Significant Other Observable Inputs (Level 2) | Other Current Assets
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	10	2
Significant Other Observable Inputs (Level 2) | Other assets
Assets, Long-term
Trading securities	0	0
Other investments	30	25
Significant Other Observable Inputs (Level 2) | Other accrued liabilities
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	19	17
Liabilities Long-term
Contingent consideration liability	0	0
Significant Other Observable Inputs (Level 2) | Other long-term liabilities
Liabilities Long-term
Deferred compensation liability	33	30
Contingent consideration liability	0	0
Significant Unobservable Inputs (Level 3)
Assets, Long-term
Total assets measured at fair value	0	0
Liabilities Long-term
Contingent consideration liability	96
Total liabilities measured at fair value	96	0
Significant Unobservable Inputs (Level 3) | Other Current Assets
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Significant Unobservable Inputs (Level 3) | Other assets
Assets, Long-term
Trading securities	0	0
Other investments	0	0
Significant Unobservable Inputs (Level 3) | Other accrued liabilities
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	0	0
Liabilities Long-term
Contingent consideration liability		0
Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc.
Liabilities Long-term
Contingent consideration liability	47
Significant Unobservable Inputs (Level 3) | Other long-term liabilities
Liabilities Long-term
Deferred compensation liability	0	0
Contingent consideration liability		$ 0
Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc.
Liabilities Long-term
Contingent consideration liability	$ 49

FAIR VALUE MEASUREMENTS, Fair_2

FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Investments
Impairment of Investments	$ 0	$ 0	$ 0	$ 0
Long-Lived Assets
Carrying value of impaired long-lived assets held for use	2	98	2	98
Fair value of impaired long-lived assets held for use	0	0	0	0
Impairment of Long-Lived Assets Held-for-use	2	98	2	98
Impairment of Long-Lived assets Held for sale	0	0	0	0
Equity Securities
Impairment of non-marketable securities	0	0	0	0
Unrealized gain on equity securities			11	27
Non-marketable equity securities carrying amount	111		111		$ 103
Fair Value, Nonrecurring
Equity Securities
Unrealized gain on equity securities	0	11	0	27
Fair Value, Measurements, Recurring
Equity Securities
Unrealized gain on equity securities	$ 11	$ 0	$ 11	$ 0

FAIR VALUE MEASUREMENTS -Contin

FAIR VALUE MEASUREMENTS -Contingent Consideration (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Fair Value, Measurements, Recurring | Other accrued liabilities
Fair Value Disclosures [Abstract]
Contingent consideration liability	$ 47	$ 0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	47	0
Fair Value, Measurements, Recurring | Other long-term liabilities
Fair Value Disclosures [Abstract]
Contingent consideration liability	49	0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	49	0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Fair Value Disclosures [Abstract]
Contingent consideration liability	96
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	96
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Other accrued liabilities
Fair Value Disclosures [Abstract]
Contingent consideration liability		0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Other accrued liabilities | Resolution Bioscience, Inc.
Fair Value Disclosures [Abstract]
Contingent consideration liability	47
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	47
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Other long-term liabilities
Fair Value Disclosures [Abstract]
Contingent consideration liability		0
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability		$ 0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Other long-term liabilities | Resolution Bioscience, Inc.
Fair Value Disclosures [Abstract]
Contingent consideration liability	49
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 49
Measurement Input, Asset Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination Contingent Consideration Liability Measurement Input	54.90%
Measurement Input, Revenue Volatility | Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination Contingent Consideration Liability Measurement Input	13.80%
Measurement Input, Revenue Volatility | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination Contingent Consideration Liability Measurement Input	14.00%

DERIVATIVES- Text (Details)

DERIVATIVES- Text (Details) $ in Millions

Apr. 05, 2021USD ($)

Jan. 21, 2021USD ($)

Sep. 06, 2019USD ($)

Sep. 15, 2016USD ($)

Apr. 30, 2021USD ($)

Apr. 30, 2020USD ($)

Apr. 30, 2021USD ($)

Apr. 30, 2020USD ($)

Aug. 16, 2019USD ($)

Feb. 01, 2016USD ($)contracts

Sep. 13, 2012USD ($)

Jul. 01, 2012USD ($)

Derivative Instruments and Hedging Activities Disclosure

Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position

$ 15

$ 15

Senior Notes 2022

Terminated Derivative Contracts

Repayments of Senior Debt

$ 300

$ 100

Aggregate face amount of debt

$ 400

Senior Notes 2022 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging

Terminated Derivative Contracts

Derivative, Notional Amount

$ 400

Senior Notes 2026 | Interest Rate Swap | Derivatives Designated as Hedging Instrument | Cash Flow Hedging

Terminated Derivative Contracts

Number of interest rate swap contracts terminated | contracts

3

Derivative, Notional Amount

$ 300

Interest rate swap payments

$ 10

Remaining gain (loss) to be amortized on derivative

5

5

Senior Notes 2029 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging

Terminated Derivative Contracts

Derivative, Notional Amount

$ 250

Interest rate swap payments

$ 6

Remaining gain (loss) to be amortized on derivative

5

5

Accumulated Other Comprehensive Income (Loss) | Foreign Exchange Contracts | Derivatives Designated as Hedging Instrument | Cash Flow Hedging

Net Investment Hedge

Gain (loss) recognized in accumulated other comprehensive loss

0

$ 2

(6)

$ 3

Accumulated Other Comprehensive Income (Loss) | Foreign Exchange Contracts | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member]

Net Investment Hedge

Gain (loss) recognized in accumulated other comprehensive loss

$ 1

$ 1

$ (3)

$ 1

DERIVATIVES- Foreign Exchange F

DERIVATIVES- Foreign Exchange Forward Contracts (Details) $ in Millions	Apr. 30, 2021USD ($)contracts
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Forward
Derivative
Number of foreign exchange forward contracts (in units) | contracts	270
Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Foreign Exchange Forward
Derivative
Number of foreign exchange forward contracts (in units) | contracts	3
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Forward
Derivative
Number of foreign exchange forward contracts (in units) | contracts	196
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Forward Contracts USD
Derivative
Derivative, Notional Amount	$ 412
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Euro | Forward Contracts USD
Derivative
Derivative, Notional Amount	77
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | British Pound | Forward Contracts USD
Derivative
Derivative, Notional Amount	56
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Canadian Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	40
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Japanese Yen | Forward Contracts USD
Derivative
Derivative, Notional Amount	98
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Korean Won | Forward Contracts USD
Derivative
Derivative, Notional Amount	63
Sell | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Chinese Yuan Renminbi | Forward Contracts USD
Derivative
Derivative, Notional Amount	97
Sell | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Forward Contracts USD
Derivative
Derivative, Notional Amount	94
Sell | Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Euro | Forward Contracts USD
Derivative
Derivative, Notional Amount	94
Sell | Derivatives Not Designated as Hedging Instruments | Forward Contracts USD
Derivative
Derivative, Notional Amount	94
Sell | Derivatives Not Designated as Hedging Instruments | British Pound | Forward Contracts USD
Derivative
Derivative, Notional Amount	12
Sell | Derivatives Not Designated as Hedging Instruments | Canadian Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	20
Sell | Derivatives Not Designated as Hedging Instruments | Japanese Yen | Forward Contracts USD
Derivative
Derivative, Notional Amount	33
Sell | Derivatives Not Designated as Hedging Instruments | Korean Won | Forward Contracts USD
Derivative
Derivative, Notional Amount	21
Sell | Derivatives Not Designated as Hedging Instruments | Swiss Franc | Forward Contracts USD
Derivative
Derivative, Notional Amount	5
Sell | Derivatives Not Designated as Hedging Instruments | Chinese Yuan Renminbi | Forward Contracts USD
Derivative
Derivative, Notional Amount	38
Sell | Derivatives Not Designated as Hedging Instruments | Swedish Krona | Forward Contracts USD
Derivative
Derivative, Notional Amount	11
Sell | Derivatives Not Designated as Hedging Instruments | Taiwan, New Dollars | Forward Contracts USD
Derivative
Derivative, Notional Amount	9
Sell | Derivatives Not Designated as Hedging Instruments | India, Rupees | Forward Contracts USD
Derivative
Derivative, Notional Amount	13
Sell | Derivatives Not Designated as Hedging Instruments | Other | Forward Contracts USD
Derivative
Derivative, Notional Amount	2
Sell | Derivatives Not Designated as Hedging Instruments | Brazil, Brazil Real | Forward Contracts USD
Derivative
Derivative, Notional Amount	6
Sell | Derivatives Not Designated as Hedging Instruments | Thailand, Baht | Forward Contracts USD
Derivative
Derivative, Notional Amount	7
Buy | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Singapore Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	15
Buy | Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Other | Forward Contracts USD
Derivative
Derivative, Notional Amount	4
Buy | Derivatives Not Designated as Hedging Instruments | Euro | Forward Contracts USD
Derivative
Derivative, Notional Amount	31
Buy | Derivatives Not Designated as Hedging Instruments | Danish Krone | Forward Contracts USD
Derivative
Derivative, Notional Amount	34
Buy | Derivatives Not Designated as Hedging Instruments | Singapore Dollar | Forward Contracts USD
Derivative
Derivative, Notional Amount	$ 18

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	$ 10	$ 2
Derivatives liabilities fair value	19	17
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	4	0
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	10	12
Derivatives Designated as Hedging Instruments | Net Investment Hedging [Member] | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	0	0
Derivatives Designated as Hedging Instruments | Net Investment Hedging [Member] | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	2	0
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	6	2
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	$ 7	$ 5

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Derivative
Loss reclassified from accumulated other comprehensive loss into cost of sales	$ (6)	$ 1	$ (14)	$ 1
Interest Expense
Derivative
Loss reclassified from accumulated other comprehensive loss into cost of sales	0	(1)	0	(1)
Cost of Products and Services
Derivative
Loss reclassified from accumulated other comprehensive loss into cost of sales	(6)	2	(14)	2
Cash Flow Hedging | Cost of Products and Services
Derivative
Cash flow hedge net gain to be reclassified within next Twelve Months	0
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive loss	0	2	(6)	3
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Interest Expense
Derivative
Loss reclassified from accumulated other comprehensive loss into cost of sales	0	(1)	0	(1)
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts | Cost of Products and Services
Derivative
Loss reclassified from accumulated other comprehensive loss into cost of sales	(6)	2	(14)	2
Loss recognized in other income (expense)	0	2	0	2
Derivatives Designated as Hedging Instrument | Net Investment Hedging [Member] | Foreign Exchange Contracts | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive loss	1	1	(3)	1
Derivatives Not Designated as Hedging Instruments | Other income (expense)
Derivative
Loss recognized in other income (expense)	$ 3	$ (1)	$ (1)	$ (3)

RETIREMENT PLANS AND POST RET_3

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Pension Plan | United States
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	$ 0	$ 0	$ 0	$ 0
Interest cost on benefit obligation	4	4	7	8
Expected return on plan assets	(8)	(7)	(15)	(15)
Amortization:
Actuarial losses	1	1	2	2
Prior service credits	0	0	0	0
Total net plan costs (benefits)	(3)	(2)	(6)	(5)
Pension Plan | Foreign Plan
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	4	5	11	12
Interest cost on benefit obligation	2	2	4	4
Expected return on plan assets	(13)	(12)	(25)	(24)
Amortization:
Actuarial losses	14	12	27	24
Prior service credits	0	0	0	0
Total net plan costs (benefits)	7	7	17	16
Other Postretirement Benefits Plan | United States
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	0	0	0
Interest cost on benefit obligation	1	1	2	2
Expected return on plan assets	(1)	(2)	(3)	(3)
Amortization:
Actuarial losses	1	1	2	2
Prior service credits	(1)	(2)	(1)	(4)
Total net plan costs (benefits)	$ 0	$ (2)	$ 0	$ (3)

RETIREMENT PLANS AND POST RET_4

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Employer Contributions)) - Pension Plan - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
United States
Defined Benefit Plan Disclosure
Employer Contributions	$ 0	$ 0	$ 0	$ 0
Expected future employer contributions	0		0
Foreign Plan
Defined Benefit Plan Disclosure
Employer Contributions	4	$ 14	9	$ 19
Expected future employer contributions	$ 13		$ 13

WARRANTIES AND CONTINGENCIES (D

WARRANTIES AND CONTINGENCIES (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Oct. 31, 2020
Movement in Standard Product Warranty Accrual
Beginning balance	$ 32	$ 32
Accruals for warranties including change in estimate	26	25
Settlements made during the period	(26)	(27)
Ending balance at end of period	32	30
Standard Product Warranty Disclosure
Accruals for warranties due within one year	31	30
Accrual for warranties due after one year	1	$ 0
Guarantees
Guarantees	$ 47		$ 43

SHORT-TERM DEBT - Credit Facili

SHORT-TERM DEBT - Credit Facility (Details) - Line of Credit [Member] - USD ($) $ in Millions	Mar. 13, 2019	Apr. 30, 2021	Apr. 21, 2021	May 01, 2020	Oct. 21, 2019
5 yr Unsecured Credit Facility
Short-term Debt
Initiation date of credit facility	Mar. 13, 2019
Maximum borrowing capacity of credit facility	$ 1,000		$ 1,350
Credit faciity terms (in years)		five
Expiration date of credit facility	Mar. 13, 2024
Amount outstanding on credit facility		$ 0
Additional Incremental Term Loan Facility
Short-term Debt
Maximum borrowing capacity of credit facility			$ 500		$ 500
Amount outstanding on credit facility		0
Commercial Paper
Short-term Debt
Maximum borrowing capacity of credit facility				$ 1,000
Amount outstanding on credit facility		$ 205
Weighted Average Interest Rate, at Point in Time		0.17%
Weighted average maturity date at a point in time		4 days

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Debt Instrument
Long-term debt	$ 2,727	$ 2,284
Senior Notes 2022
Debt Instrument
Long-term debt	0	400
Senior Notes 2023
Debt Instrument
Long-term debt	599	598
Senior Notes 2026
Debt Instrument
Long-term debt	298	298
Senior Notes 2029
Debt Instrument
Long-term debt	494	493
Senior Notes 2030
Debt Instrument
Long-term debt	495	495
Senior Notes 2031
Debt Instrument
Long-term debt	$ 841	$ 0

LONG-TERM DEBT - Text (Details)

LONG-TERM DEBT - Text (Details) - USD ($) $ in Millions	Apr. 05, 2021	Mar. 12, 2021	Jan. 21, 2021	Sep. 13, 2012	Apr. 30, 2021	Apr. 30, 2021	Apr. 30, 2020
Debt Instrument
Early Repayment of Senior Debt						$ 417	$ 0
Loss on extinguishment of debt						17	$ 0
Senior Notes 2022
Debt Instrument
Issuance date of debt				Sep. 13, 2012
Aggregate face amount of debt				$ 400
Percentage Of Face Amount Of Senior Note Instrument Issued				99.80%
Maturity date of debt				Oct. 1, 2022
Fixed interest rate per annum				3.20%
Debt interest payment frequency				semi-annually
Date interest payment commenced				Apr. 1, 2013
Repayments of Senior Debt	$ 300		$ 100
Early Repayment of Senior Debt						417
Loss on extinguishment of debt					$ 12	17
Payment of accrued and unpaid interest						$ 1
Senior Notes 2031
Debt Instrument
Issuance date of debt		Mar. 12, 2021
Aggregate face amount of debt		$ 850
Percentage Of Face Amount Of Senior Note Instrument Issued		99.822%
Maturity date of debt		Mar. 12, 2031
Fixed interest rate per annum		2.30%
Date interest payment commenced		Sep. 12, 2021

STOCKHOLDERS' EQUITY - Stock Re

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020	Feb. 18, 2021	Nov. 19, 2018
2019 Repurchase Program [Member]
Share repurchase program
Share repurchase program authorized amount						$ 1,750
Shares repurchased and retired during period, (Shares)	164,422	1,663,000	3,050,000	2,389,000
Shares repurchased and retired during period, (Value)	$ 21	$ 126	$ 365	$ 186
Remaining authorized repurchase amount under share repurchase program					$ 193
2021 Repurchase Program [Member]
Share repurchase program
Share repurchase program authorized amount					$ 2,000
Shares repurchased and retired during period, (Shares)	1,388,000		1,388,000
Shares repurchased and retired during period, (Value)	$ 174		$ 174
Remaining authorized repurchase amount under share repurchase program	$ 1,826		$ 1,826

STOCKHOLDER"S EQUITY - Dividend

STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	May 19, 2021	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Dividends Paid
Cash dividends paid per common share		$ 0.194	$ 0.180	$ 0.388	$ 0.360
Aggregate amount of cash dividends paid		$ 59	$ 55	$ 118	$ 111
Dividends Declared
Dividends Declared per share		$ 0.194	$ 0.18	$ 0.388	$ 0.36
Subsequent Event [Member]
Dividends Declared
Date Dividends Declared	May 19, 2021
Dividends Declared per share	$ 0.194
Aggregate Dividends declared (Cash)	$ 59
Payment Date of Declared Dividends	Jul. 28, 2021
Dividends Declared Date of Record	Jul. 6, 2021

STOCKHOLDER'S EQUITY - Accumula

STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Beginning Balance	$ (469)		$ (522)
Other comprehensive income (loss) before reclassifications	2		35
Amounts reclassified out of accumulated other comprehensive income (loss)	21		45
Tax expense (benefit)	(6)		(10)
Other comprehensive income (loss)	17	$ (17)	70	$ (24)
Ending Balance	(452)		(452)
Foreign Currency Translation
Beginning Balance	(152)		(194)
Other comprehensive income (loss) before reclassifications	2		44
Amounts reclassified out of accumulated other comprehensive income (loss)	0		0
Tax expense (benefit)	0		0
Other comprehensive income (loss)	2		44
Ending Balance	(150)		(150)
Prior Service Credits
Beginning Balance	125		125
Other comprehensive income (loss) before reclassifications	0		0
Amounts reclassified out of accumulated other comprehensive income (loss)	(1)		(1)
Tax expense (benefit)	0		0
Other comprehensive income (loss)	(1)		(1)
Ending Balance	124		124
Actuarial Losses
Beginning Balance	(433)		(442)
Other comprehensive income (loss) before reclassifications	0		(3)
Amounts reclassified out of accumulated other comprehensive income (loss)	16		32
Tax expense (benefit)	(4)		(8)
Other comprehensive income (loss)	12		21
Ending Balance	(421)		(421)
Unrealized Gains (Losses) on Derivatives
Beginning Balance	(9)		(11)
Other comprehensive income (loss) before reclassifications	0		(6)
Amounts reclassified out of accumulated other comprehensive income (loss)	6		14
Tax expense (benefit)	(2)		(2)
Other comprehensive income (loss)	4		6
Ending Balance	$ (5)		$ (5)

STOCKHOLDERS' EQUITY - Reclassi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized gain (loss) on derivatives	$ (6)	$ 1	$ (14)	$ 1
Reclassification of (gains) and losses into earnings related to derivative instruments, tax	2	0	4	0
Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax	(4)	1	(10)	1
Actuarial net loss	(16)	(14)	(32)	(28)
Prior service benefit	1	2	1	4
Actuarial net loss and prior service benefit reclassified, before tax	(15)	(12)	(31)	(24)
Tax on actuarial net loss and prior service benefit reclassified	4	2	8	8
Actuarial net loss and prior service benefit reclassified, net of tax	(11)	(10)	(23)	(16)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(15)	(9)	(33)	(15)
Cost of Products and Services
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized gain (loss) on derivatives	(6)	2	(14)	2
Interest Expense
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized gain (loss) on derivatives	$ 0	$ (1)	$ 0	$ (1)

SEGMENT INFORMATION - Profitabi

SEGMENT INFORMATION - Profitability (Details) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021USD ($)	Apr. 30, 2020USD ($)	Apr. 30, 2021USD ($)	Apr. 30, 2020USD ($)
Segment Reporting Information
Number of operating segments	3
Segment Reporting Information
Net revenue	$ 1,525	$ 1,238	$ 3,073	$ 2,595
Income from operations	288	102	616	317
Life Sciences and Applied Markets
Segment Reporting Information
Net revenue	674	526	1,396	1,164
Income from operations	154	98	353	256
Diagnostics and Genomics
Segment Reporting Information
Net revenue	315	263	609	512
Income from operations	69	57	124	91
Agilent CrossLab
Segment Reporting Information
Net revenue	536	449	1,068	919
Income from operations	141	122	283	241
Segment Total
Segment Reporting Information
Net revenue	1,525	1,238	3,073	2,595
Income from operations	$ 364	$ 277	$ 760	$ 588

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2021	Apr. 30, 2020	Apr. 30, 2021	Apr. 30, 2020
Reconciliation of Operating Profit from Segments to Consolidated
Total reportable segment's income from operations	$ 364	$ 277	$ 760	$ 588
Transformational initiatives	(9)	(15)	(20)	(28)
Amortization of intangible assets related to business combinations	(46)	(46)	(90)	(94)
Acquisition and integration costs	(13)	(11)	(22)	(24)
Asset Impairment Charges	(2)	(99)	(2)	(99)
Business exit and divestiture costs	(3)	0	(4)	0
Other	(3)	(4)	(6)	(26)
Interest income	1	3	1	6
Interest expense	(20)	(20)	(39)	(40)
Other income (expense), net	4	36	7	57
Income before taxes, as reported	$ 273	$ 121	$ 585	$ 340

SEGMENT INFORMATION - Segment A

SEGMENT INFORMATION - Segment Assets (Details) - USD ($) $ in Millions	Apr. 30, 2021	Oct. 31, 2020
Segment Reporting Information
Assets	$ 10,398	$ 9,627
Life Sciences and Applied Markets
Segment Reporting Information
Assets	3,119	3,143
Diagnostics and Genomics
Segment Reporting Information
Assets	3,262	2,515
Agilent CrossLab
Segment Reporting Information
Assets	1,425	1,375
Segment Total
Segment Reporting Information
Assets	$ 7,806	$ 7,033